Pandemic Influenza Preparedness
Strategy and Plan



- International Surveillance
- Domestic Surveillance
- Vaccine
- Antivirals
- Communications
- State and Local Preparedness

Pandemic Vaccine Evaluation
Preliminary Results

- Sanofi Inactivated H5N1 Subunit Vaccine
  - Evaluated in 451 healthy young adults; well-tolerated overall
  - Two 90 µg doses induced an immune response predictive of protection
- Chiron Inactivated H9N2 Subunit Vaccine with MF59 Adjuvant
  - Evaluated in 96 healthy young adults; well-tolerated overall
  - Single 3.75 µg dose induced an immune response predictive of protection

Influenza Vaccines: Stockpile and Strategy

Stockpile:

- Bulk H5N1 vaccine contracts:
  - Sanofi, $100 million
  - Chiron, $62.5 million

Strategy:

- Manufacture 20 million courses of pre-pandemic vaccine
- Create capacity to manufacture 300 million courses of vaccine within six months of pandemic outbreak
- Accelerate development of adjuvants, cell culture-based production technology, and other vaccine approaches

Antiviral Therapies for Influenza



Influenza Treatments: Stockpile and Strategy

Stockpile:

- Tamiflu: 2.75 million courses in Strategic National Stockpile with total to equal 4.3 million courses before the end of 2005

Strategy:

- Set national goal of 81 million courses of antivirals
  - 75 million courses to treat 25 percent of U.S. population
  - 6 million courses to be used to contain an initial U.S. outbreak
- Accelerate development of promising new antiviral candidates

The Influenza Pandemic of 1918-1919



- 25-30% of world's population (~500 million people) fell ill
- >40 million deaths worldwide; ~60 percent in people ages 20-45
- >500,000 deaths in United States; 196,000 in October, 1918 alone

Source: WHO, 1/2005